Extracorporeal whole-blood immunoadsorption enhances radioimmunotargeting of iodine-125-labeled BR96-biotin monoclonal antibody
(1997) In Journal of Nuclear Medicine 38(6). p.895-901- Abstract
- This study investigates the efficacy of tumor radioimmunotargeting with 125I-labeled BR96-biotin monoclonal antibody using a new method, whole-blood immunoadsorption (WBIA), based on direct adsorption of unbound monoclonal antibody (MAb) from blood without preceding separation of plasma. METHODS: Highly tumor-reactive, internalizing, chimeric BR96 MAb of isotype IgG1 binds to a tumor-associated Lewis-type (Le(Y)) cell surface antigen. Forty-six Brown Norwegian male rats were inoculated intramuscularly and beneath the liver or kidney capsule with syngeneic rat colon carcinoma BN7005, expressing Lewis-type antigen, and investigated. The rats were injected intravenously with 3.5-4.5 MBq 125I-labeled BR96-biotin. Twenty of the rats underwent... (More)
- This study investigates the efficacy of tumor radioimmunotargeting with 125I-labeled BR96-biotin monoclonal antibody using a new method, whole-blood immunoadsorption (WBIA), based on direct adsorption of unbound monoclonal antibody (MAb) from blood without preceding separation of plasma. METHODS: Highly tumor-reactive, internalizing, chimeric BR96 MAb of isotype IgG1 binds to a tumor-associated Lewis-type (Le(Y)) cell surface antigen. Forty-six Brown Norwegian male rats were inoculated intramuscularly and beneath the liver or kidney capsule with syngeneic rat colon carcinoma BN7005, expressing Lewis-type antigen, and investigated. The rats were injected intravenously with 3.5-4.5 MBq 125I-labeled BR96-biotin. Twenty of the rats underwent WBIA starting 5 or 12 hr after injection. About six blood volumes were passed through an avidin-gel adsorption column during 2 hr. RESULTS: By using WBIA, whole-body radioactivity was reduced by 50%, and plasma activity by 85%. Both directly after completion of WBIA and 33 hr later, the activity uptake in tumors manifested only a nonsignificant decrease as compared with corresponding controls (p > 0.05) and had approximately similar time-activity curves. Uptake ratios for tumor (T):bone marrow, T:liver, T:kidney and T:lung were enhanced 2.3- to 3.5-fold in all three tumor models, as compared with controls. The ratio of liver tumor to bone marrow was improved from 10:1 to 30:1. CONCLUSION: This new method of WBIA yields significantly improved radioimmunotargeting of highly tumor-reactive, internalizing MAb BR96. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/1111662
- author
- Garkavij, Martin ; Tennvall, Jan LU ; Strand, Sven-Erik LU ; Sjögren, Hans Olov LU ; JianQing, Chen ; Nilsson, Rune LU and Isaksson, Martin
- organization
- publishing date
- 1997
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- tumor, rat, radioimmunotargeting, MAb BR96, immunoadsorption
- in
- Journal of Nuclear Medicine
- volume
- 38
- issue
- 6
- pages
- 895 - 901
- publisher
- Society of Nuclear Medicine
- external identifiers
-
- pmid:9189138
- scopus:0030952707
- ISSN
- 0161-5505
- language
- English
- LU publication?
- yes
- id
- 6d7f7a58-0247-478e-9ed2-279bf3fc91b2 (old id 1111662)
- alternative location
- http://jnm.snmjournals.org/cgi/reprint/38/6/895
- date added to LUP
- 2016-04-01 15:39:39
- date last changed
- 2022-01-28 06:27:31
@article{6d7f7a58-0247-478e-9ed2-279bf3fc91b2, abstract = {{This study investigates the efficacy of tumor radioimmunotargeting with 125I-labeled BR96-biotin monoclonal antibody using a new method, whole-blood immunoadsorption (WBIA), based on direct adsorption of unbound monoclonal antibody (MAb) from blood without preceding separation of plasma. METHODS: Highly tumor-reactive, internalizing, chimeric BR96 MAb of isotype IgG1 binds to a tumor-associated Lewis-type (Le(Y)) cell surface antigen. Forty-six Brown Norwegian male rats were inoculated intramuscularly and beneath the liver or kidney capsule with syngeneic rat colon carcinoma BN7005, expressing Lewis-type antigen, and investigated. The rats were injected intravenously with 3.5-4.5 MBq 125I-labeled BR96-biotin. Twenty of the rats underwent WBIA starting 5 or 12 hr after injection. About six blood volumes were passed through an avidin-gel adsorption column during 2 hr. RESULTS: By using WBIA, whole-body radioactivity was reduced by 50%, and plasma activity by 85%. Both directly after completion of WBIA and 33 hr later, the activity uptake in tumors manifested only a nonsignificant decrease as compared with corresponding controls (p > 0.05) and had approximately similar time-activity curves. Uptake ratios for tumor (T):bone marrow, T:liver, T:kidney and T:lung were enhanced 2.3- to 3.5-fold in all three tumor models, as compared with controls. The ratio of liver tumor to bone marrow was improved from 10:1 to 30:1. CONCLUSION: This new method of WBIA yields significantly improved radioimmunotargeting of highly tumor-reactive, internalizing MAb BR96.}}, author = {{Garkavij, Martin and Tennvall, Jan and Strand, Sven-Erik and Sjögren, Hans Olov and JianQing, Chen and Nilsson, Rune and Isaksson, Martin}}, issn = {{0161-5505}}, keywords = {{tumor; rat; radioimmunotargeting; MAb BR96; immunoadsorption}}, language = {{eng}}, number = {{6}}, pages = {{895--901}}, publisher = {{Society of Nuclear Medicine}}, series = {{Journal of Nuclear Medicine}}, title = {{Extracorporeal whole-blood immunoadsorption enhances radioimmunotargeting of iodine-125-labeled BR96-biotin monoclonal antibody}}, url = {{http://jnm.snmjournals.org/cgi/reprint/38/6/895}}, volume = {{38}}, year = {{1997}}, }